175 studies on Mgf curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 19 published Mgf COA source records from third-party laboratories, covering 8 publicly attributable vendor identities. Across 17 records with positive numeric purity, the arithmetic mean is 99.66%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 2 records report measured amount more than 10% below the label. The latest recorded test date is 2026-07-06. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $10.50 | $10.50–$10.50 | $5.25 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-07-06. Aggregate calculated: 2026-10-19T05:12:07.751290+00:00. Calculation time is not a laboratory observation date.
Within that total, 5 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 4 | 99.72% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 4 | 99.72% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #112030 · #75094 (99.624%) · #84919 (99.648%) · #90666 (99.95%) · #86307 (99.95%) · #15169 (99.491%)
Sandostatin LAR is a well-established treatment for acromegaly, and this study aimed to refine our understanding of its comprehensive benefits beyond just hormone suppression. Demonstrating clear improvements in metab…
This study is significant because it investigated the impact of very early initiation of growth hormone therapy in Turner Syndrome, a critical period for growth and development. The findings, once fully published, cou…
This study is significant because it explores the practical application of lanreotide Autogel 120 mg at extended dosing intervals, potentially offering a more convenient and less burdensome treatment schedule for pati…
The successful completion of this Phase 3 trial is a significant step towards developing an effective treatment for primary IGF-1 deficiency, a condition with limited therapeutic options. rhIGF-1 (mecasermin) holds su…
This pioneering single-patient study represents an early, crucial exploration into a novel therapeutic approach for a complex and rare genetic disease. Targeting low IGF-1 levels in Werner's Syndrome patients with ost…
This Phase II trial is profoundly important because it seeks to identify a safer, more tolerable preventative strategy for breast cancer in high-risk post-menopausal women. Current preventative doses of Exemestane and…
The investigation of novel agents like CP-751,871 in combination with established chemotherapy is crucial for improving outcomes in advanced NSCLC, where new therapeutic strategies are desperately needed. Understandin…
This is a proceedings publication from the 49th Annual Meeting of the Austrian Society of Surgery, held in Innsbruck, May 21-23, 2008, guest-edited by Beate Neuhauser, Dietmar Öfner, Elfriede Ruttmann-Ulmer, and Anton…
Understanding the acute molecular response to muscle reloading is critical for optimizing rehabilitation protocols after periods of disuse. This study highlights that autophagy and myogenesis pathways are rapidly acti…
Accurate and reliable non-invasive prenatal screening for 22q11.2 deletion syndrome is crucial for early diagnosis and informed decision-making for expectant parents. The internal analytical verification of a targeted…
This synthesis of evidence underscores the critical role of growth hormone (GH) in driving breast cancer progression, metastasis, and angiogenesis, moving beyond the traditional focus on steroid hormones. Understandin…
This comprehensive review highlights the critical role of IGF-1 in MASLD pathogenesis, suggesting it's not just a correlative factor but potentially a key player. The most significant implication is that IGF-1 levels …
Understanding how different exercise types acutely impact cerebral blood flow is crucial for developing targeted interventions to maintain cognitive function in healthy aging. If this study demonstrates significant im…
The development of effective and safe strategies for rapid weight loss in severe obesity is crucial for improving patient health and preparing for bariatric surgery or other long-term interventions. If the results of …
The establishment of accurate normative ranges for IGF-1, IGFBP-3, and ALS is profoundly important for pediatric endocrinology. These reference values provide clinicians with the necessary tools to differentiate betwe…
This global registry represents a crucial step in understanding the long-term safety and effectiveness of Increlex® for SPIGFD. By collecting data from a large, diverse patient population over many years, it can ident…
If successful, this research could provide a non-pharmacological strategy to mitigate breast cancer risk in individuals with BRCA mutations. Understanding the impact of diet on biomarkers like IGF-I could empower muta…
The demonstration of safety and feasibility for the Fasting Mimicking Diet (FMD) in cancer patients is a significant step, as it suggests that this non-pharmacological intervention could be safely integrated into exis…
This Phase 4 study is significant because it investigates a sequential therapy approach for Thyroid Associated Ophthalmopathies (TAO), a debilitating condition often resistant to current treatments. IBI311, as an anti…
Understanding the role of post-exercise protein in bone health could significantly impact recovery protocols for endurance runners and other athletes, potentially reducing the risk of stress fractures and osteoporosis…
Free, no account — handy when you're working with Mgf.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account